BioXcel Therapeutics

BTAI

Market cap $41.8M

1.91 USD

-0.04

2.05%

At close Updated Nov 25, 4:00 PM EST

Pre-market

After hours

1.92

+0.01

0.52%

1 day

-2.05%

5 days

3.8%

1 month

-16.23%

3 months

-62.98%

6 months

37.41%

Year to date

-69.54%

1 year

-74.6%

5 years

-99.73%

10 years

-98.92%

About: BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Employees: 37

Healthcare Biotechnology